Phone: +44 141 899 0081

Archive

Home / Month: December 2016

ASH, SABCS, IASLC WCLC Highlights

ASH 2016 Highlights, December 3-6 2016AbbVie Inc. & Janssen – Ibrutinib (IMBRUVICA®). PCYC-1121-CA Phase II trial assessed ibrutinib as a single-agent treatment for marginal zone lymphoma patients that received one or more prior therapies including at least one CD20-directed regimen. In the study, 79% of